ZARS Pharma is a specialty pharmaceutical company focused on the development and commercialization of topically administered drugs using our proprietary drug delivery technologies, primarily in the area of pain management. We have developed a portfolio of proprietary products and product candidates based on our Controlled Heat-Assisted Drug Delivery (CHADD™) technology and our cream technologies (Peel and DuraPeel™) that transform, or phase-change, from an initial liquid phase to a solid phase during application. Our products and product candidates include two products that have been approved for marketing (Pliaglis™, and Synera™, which is marketed as Rapydan™ in Europe)